For the first time, U.S. regulators have cleared Medtronic's controversial Infuse Bone Graft biologic product for lower-back surgery for use with plastic — rather than titanium — spinal components.

Medtronic has pulled one of its most controversial products, Infuse Bone Graft, off the market in Australia as regulators there investigate why the company was widely selling it without a required ...

PERTH, Australia – Australia’s Therapeutic Goods Administration (TGA) has initiated proceedings in the Federal Court of Australia against Medtronic Australasia Pty Ltd. for alleged unlawful supply of ...

A study comparing the safety and effectiveness of Infuse Bone Graft material to autogenous bone graft when used in maxillary sinus floor augmentation demonstrated that Infuse has similar rates of ...

MINNEAPOLIS (AP) — Medtronic says federal prosecutors have closed their investigation of the Minneapolis-based company’s InFuse bone graft. The medical device maker was being investigated by the U.S.

Medtronic ($MDT) must fork over $85 million to put a massive shareholder class action lawsuit behind it concerning the company's Infuse bone graft material. While ...

Minneapolis-based Medtronic faces approximately 700 lawsuits involving 1,000 patients claiming personal injury due to the company's Infuse bone graft product, according to the company's SEC filing for ...

MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) today announced that it has received regulatory approval from the U.S. Food and Drug Administration (FDA) to begin marketing INFUSE® Bone ...

DUBLIN and CHICAGO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced U.S. FDA approval of a prospective, randomized pivotal clinical trial for the use of Infuse™ Bone Graft ...